Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Daiichi Sankyo to proceed with phase III trial of cancer drug

Daiichi Sankyo to proceed with phase III trial of cancer drug

4th August 2010

Daiichi Sankyo has announced plans to progress its non-small cell lung cancer drug ARQ 197 to phase III testing in a new clinical trial.

The company, in association with development partner ArQule, is to compare the efficacy of a combination of erlotinib plus ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase, against erlotinib plus placebo.

It is proceeding with this trial based on positive findings from a recently concluded phase II study, in which the drug demonstrated promising results in terms of progression-free survival among patients.

Dr Kazunori Hirokawa, global head of research and development at Daiichi Sankyo, said: “Based on these results, we are developing plans to support a phase III clinical programme and bring new hope to patients with this disease.”

ArQule and Daiichi Sankyo have been working together on developing ARQ 197 since 2008.

Earlier this week, Daiichi Sankyo announced that it will create a new joint venture with the Kitasato Institute in order to research and develop new vaccines.ADNFCR-8000103-ID-800012197-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.